How to promote the accessibility of technology in the era of hESC patents-A comparative analysis of the systems of the US and China

Wei Zhang; Jiajv Chen; Wei Li; Hanyang Zhang

doi:10.1016/j.stemcr.2023.08.013

How to promote the accessibility of technology in the era of hESC patents-A comparative analysis of the systems of the US and China

Stem Cell Reports. 2023 Oct 10;18(10):1899-1904. doi: 10.1016/j.stemcr.2023.08.013. Epub 2023 Sep 21.

Authors

Wei Zhang¹, Jiajv Chen², Wei Li³, Hanyang Zhang⁴

Affiliations

¹ School of Law, Zhejiang Gongshang University, Hangzhou 310018, China.
² School of Law, Renmin University of China, Beijing 100872, China; Institute of Intellectual Property, University of Science and Technology of China, Hefei 230022, China.
³ Intellectual Property Research Institute, Jinan University, Guangzhou 510632, China. Electronic address: iprecht@126.com.
⁴ Institute of Intellectual Property, University of Science and Technology of China, Hefei 230022, China.

Abstract

We have entered the era of human embryonic stem cell (hESC) patents and the focus of discussion has shifted to how to rebalance interests. A potential way is to limit hESC patents and seek more effective utilization forms, such as ethical limitation, compulsory licensing, antimonopoly law regulation, experimental exception, and open licensing. This paper compares the restrictive measures in two major hESC markets, the United States and China, and explores the possibility of a balanced interests system.

Publication types

Review

MeSH terms

China
Human Embryonic Stem Cells*
Humans
Technology
United States